首页 | 本学科首页   官方微博 | 高级检索  
检索        

K—ras基因与结直肠癌疗效
引用本文:于法常,李胜,牛作兴.K—ras基因与结直肠癌疗效[J].国际肿瘤学杂志,2014(3):214-216.
作者姓名:于法常  李胜  牛作兴
作者单位:[1]济南大学山东省医学科学院医学与生命科学学院,250062 [2]山东省肿瘤医院内科四病区 ,250062 [3]山东省医学科学院科技开发处,250062
摘    要:K—ras基因是一种癌基因,促进细胞生长、分化,基因的突变使ras蛋白丧失GTP酶活性,导致细胞的异常生长、分化,促进癌的发生,同时导致使用抗表皮生长因子受体(EGFR)多克隆抗体药物治疗的结直肠癌患者无明显获益。结直肠癌不同实体肿瘤的K—ras基因突变率不同,K—ras基因野生型或突变型对治疗方案选择及预后具有重要意义,突变型患者使用抗EGFR抗体治疗效果差,对5-Fu、FOLFOX疗效尚无一致定论。

关 键 词:结直肠肿瘤  治疗结果  K—ras基因

K-ras gene and colorectal cancer therapeutic effect
Yu Fachang,Li Sheng,Niu Zuoxing.K-ras gene and colorectal cancer therapeutic effect[J].Journal of International Oncology,2014(3):214-216.
Authors:Yu Fachang  Li Sheng  Niu Zuoxing
Institution:. Ji' nan University Shandong Academy of Medical Sciences-Medicine and Life Science; Department of Medicine, Shandong Cancer Hospital, Ji'nan 250062, China
Abstract:K-ras gene is one of oncogenes, which promotes cells growth and differentiation. Ras protein loses the activity of GTP enzyme because of K-ras mutations, and that may cause abnormal growth, differ- entiation of cells and promote the occurrence of tumor. Patients with colorectal carcinoma that carry mutations in K-ras gene do not benefit from the administration of anti-epidermal growth factor receptor (EGFR) polyclonal antibodies. Different solid tumors of colorectal carcinoma have different K-ras mutation rates. Different geno- types of K-ras gene (wild-type or K-ras mutant type) affect significantly on treatment options and prognosis. The efficacy of mutant type patients with anti-EGFR antibodies is poor, and the therapeutic effects of 5-FU and FOLFOX are still unclear.
Keywords:Colorectal neoplasms  Treatment outcome  K-ras gene
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号